Predicting radionecrosis and recurrent disease through Amide Proton Transfer weighted imaging in brain metastases
Lucia Nichelli1,2, Julian Jacob3, Delphine Leclerq1, Farhat Benbelkacem4, Stéphane Lehéricy1,2, and Stefano Casagranda5
1Department of Neuroradiology, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, Sorbonne Université, Paris, Paris, France, 2Paris Brain Institute – Institute du Cerveau (ICM), Centre de NeuroImagerie de Recherche (CENIR), F-75013, Paris, France, 3Department of Radiation-Oncology, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles-Foix, Sorbonne Université, Paris, France, 4Siemens Healthcare SAS, Saint-Denis, Paris, France, 5Department of Research & Innovation, Olea Medical, La Ciotat, France
Distinguishing tumor recurrence from radionecrotic injury of pre-irradiated brain metastases is fundamental to provide optimal patient care. Unfortunately, this distinction is often hard to make even with advanced MRI multimodal protocols. This study aims to evaluate APTw imaging in predicting the differentiation between radio-induced tissue changes from tumor progression at 3T in 20 pre-irradiated metastases. Results show that APTw metrics can significantly separate these two common radiological entities (p<0.0001) and suggest the use of fluid-suppressed APTw to reach higher discriminating values.
This abstract and the presentation materials are available to members only;
a login is required.